Anna French, PhD
Anna French, PhD is a Partner at Qiming Venture Partners USA, and is based in Cambridge, MA. Prior to joining the Qiming team in 2017, Anna was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and operations. She also led a global industry-academic consortium focused on cell therapy commercialization.
Anna earned a D.Phil (PhD) from the University of Oxford, UK where her research focused on hematological differentiation of human induced pluripotent stem (iPS) cells. She has over 20 publications in the field of stem cell research.
Anna currently serves on the boards of WindMIL Therapeutics and Jasper Therapeutics and is a board observer with Talaris Therapeutics, Cadent Therapeutics, and PlateletBio.